Sánchez-Tabernero Sara, García-Alvarez Ciro, Muñoz-Moreno Ma Fe, Diezhandino Patricia, Alonso-Martínez Pilar, de Frutos-Baraja Jesus M, López-Lara Francisco, Saornil Maria A
Servicio de Oftalmología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Unidad de Tumores Intraoculares del Adulto, Servicio de Oftalmología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Am J Ophthalmol. 2017 Aug;180:39-45. doi: 10.1016/j.ajo.2017.05.019. Epub 2017 May 29.
To describe the time, frequency, and clinical characteristics of treatment failure after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referral ocular oncology unit.
Prospective, consecutive, interventional case series.
Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcleral brachytherapy were included. Demographic data collection, ophthalmic evaluation, ultrasound scan, and systemic studies were performed at baseline, every 6 months thereafter for 5 years, and subsequently at annual intervals. Recurrence was defined as presence of tumor growth after treatment. Baseline analysis was performed by descriptive methods and survival by Kaplan-Meier curves.
From 732 patients diagnosed with uveal melanoma, 311 were treated with brachytherapy. In the follow-up (mean 79 months, standard deviation = 55), 16 local tumor recurrences (5.1%) were detected. All relapsing patients had choroidal tumors and 15 presented with visual symptoms. All patients were treated with I-125 brachytherapy, and 2 received associated transpupillary thermotherapy. All the eyes were enucleated after recurrence. Kaplan-Meier analysis showed a mean time of recurrence of 3.7 years (standard deviation = 2.94 years, ranging from 1 to 12 years). Three patients had metastasis in the follow-up. Kaplan-Meier analysis showed worse survival for patients with recurrence.
Local treatment failure was a relatively infrequent event after I-125 brachytherapy in our series. Recurrences appear not only early but also late in the follow-up. They do not have a distinctive clinical pattern and are associated with poorer survival.
描述在西班牙一家转诊眼科肿瘤中心接受治疗并随访的葡萄膜黑色素瘤患者,接受碘 - 125近距离放射治疗后治疗失败的时间、频率和临床特征。
前瞻性、连续性、干预性病例系列研究。
纳入1995年至2016年诊断为葡萄膜黑色素瘤并接受巩膜近距离放射治疗的患者。在基线时、此后5年每6个月以及随后每年进行人口统计学数据收集、眼科评估、超声扫描和全身检查。复发定义为治疗后出现肿瘤生长。采用描述性方法进行基线分析,用Kaplan - Meier曲线分析生存率。
在732例诊断为葡萄膜黑色素瘤的患者中,311例接受了近距离放射治疗。在随访中(平均79个月,标准差 = 55个月),检测到16例局部肿瘤复发(5.1%)。所有复发患者均为脉络膜肿瘤,15例出现视觉症状。所有患者均接受碘 - 125近距离放射治疗,2例接受了相关的经瞳孔温热疗法。复发后所有患眼均被摘除。Kaplan - Meier分析显示复发的平均时间为3.7年(标准差 = 2.94年,范围为1至12年)。3例患者在随访中发生转移。Kaplan - Meier分析显示复发患者的生存率较差。
在我们的系列研究中,碘 - 125近距离放射治疗后局部治疗失败是相对少见的事件。复发不仅出现在随访早期,也出现在晚期。它们没有独特的临床模式,且与较差的生存率相关。